Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial.

@article{Murphy1988HormonerefractoryMP,
  title={Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial.},
  author={Gerald P. Murphy and Roger L. Priore and Peter T. Scardino},
  journal={Urology},
  year={1988},
  volume={32 1},
  pages={33-40}
}
From 1982 to 1985, the National Prostatic Cancer Treatment Group conducted a randomized prospective trial of single-agent or combination chemotherapy in 180 patients with metastatic prostatic disease refractory to hormonal therapy. All three of the treatment regimens, methotrexate, Adriamycin plus cyclophosphamide, cis-platinum plus 5-fluorouracil plus cyclophosphamide, showed similar survival and progression-free survival intervals. Future studies utilizing these or other agents, in similar or… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2000

Similar Papers

Loading similar papers…